A Study in Patients With Advanced Breast Cancer
A Phase 1 Study to Determine Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of SCO-120 in Hormone Receptor Positive, HER-2 Negative Advanced Breast Cancer Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Head, Clinical Developement
- Phone Number: 5678 9122 66455645
- Email: clinical.trials@sparcmail.com
Study Locations
-
-
Karnataka
-
Bangalore, Karnataka, India, 560027
- Healthcare Global Enterprises Ltd
-
-
Maharashtra
-
Nashik, Maharashtra, India, 422002
- HCG Manavata Cancer Centre
-
Pune, Maharashtra, India, 411004
- LMMF's Deenanath Mangeshkar Hospital & Research Centre
-
Pune, Maharashtra, India, 411013
- Noble Hospital Pvt. Ltd.,
-
-
-
-
California
-
Newport Beach, California, United States, 92663
- Hoag Memorial Hospital Presbyterian
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- The University of Chicago
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
All 3 parts of Study:
- Male or females, Age 18 years or older
- Histologically or cytologically diagnosed with ER+/HER2- adenocarcinoma of the breast cancer with an evidence of metastatic/loco-regionally recurrent disease/unresectable advanced disease not amenable to treatment with curative intent
- Documentation of ER-positive, HER2-negative status determined based on a biopsy performed at or after diagnosis of local or metastatic recurrence, utilizing an assay consistent with local standards
- Not more than 3 prior chemotherapeutic regimens
- ECOG performance status 0-1.
- Resolution of all adverse events of prior therapy or surgical procedures to National Cancer Institute (NCI) CTCAE v 5.0 Grade ≤1 (except alopecia)
- Adequate organ and immune system function as indicated by laboratory values
- Patients of childbearing potential must practice an acceptable method of birth control as judged by the Investigator
- Female subjects must be non-lactating and non-breast feeding
- Male subjects should not father a child and must practice an acceptable method of birth control measures Willing and available to participate for the entire study
- Willing and able to comply with protocol requirements
For Part 1& 2:
- Patient must have evaluable disease (according to RECIST 1.1).
- Documented disease progression or resistance to at least 1 prior endocrine therapy (with or without CDK 4/6 therapy).
For Part 3
- Patient must have measurable lesions (according to RECIST 1.1)
- Part 3a: HR+ve, HER2- MBC patients with ESR1 mutations, resistance to atleast one priro endocrine therapy
- Part 3b: HR+ve HER2- MBC patients resistant to atleast one priro endocrine therapy
- Part 3c: HR+ve HER2- MBC patients resistant to atleast one priro endocrine therapy, disease progression on Fulvestrant and CDK4/6i
- Part 3d: Brain metastases secondary to ER+ve HER-ve Breast Cancer:
Measurable brain lesion (≥ 1) as per RANO-BM Criteria, Tretament naive/ Treated- Stable/ Not requiring immediate local therapy known/ Suspected leptomeningeal disease on Stable corticosteriod dose for 7 days prior screeing
Exclusion Criteria:
All 3 parts of Study
- Major surgery <4 weeks of C1D1
- Evidence of organ dysfunction or inadequate bone marrow reserve or any clinically significant finidngs
- Patients with visceral crisis or impending visceral crisis and rapidly progressing disease
- Serology tests +ve for HIV, HCV, HBsAg
- Inability to swallow oral medication
- H/o any relevant allergy/hypersensitivity/idiosyncrasy to drugs/ chemically related to Study drug or its excipients
- Received an IMP within 30 days/5 half life to C1D1
- Prior treatment with other oral SERDs
- Use of concomitant medication that might reasonably influence the results or interpretation of the study
- Requires concurrent systemic anticancer treatment at any time during the study treatment period
- Known or suspected history of significant drug abuse/Alcohol as judged by the Investigator
- Known or suspected history of excessive intake of alcohol in the 12 months prior to study entry
- Malabsorption syndrome/IBD/other illness that would affect oral absorption of Study drug
- Uncontrolled intercurrent illness that would limit compliance with study requirements / have impact on endpoints / safety
- ≤6 months H/o MI/unstable angina, ongoing > G2 cardiac dysrhythmia, prolonged QTcF/ uncontrolled AF, coronary/peripheral artery bypass graft, HF of NYHA_Class II or greater and CVA (+TIA)
- H/o Endometrial intraepithelial neoplasia, other malignancy < 5 yrs prior to enrollment
- Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases, or leptomeningeal disease as indicated by clinical symptoms (not applicable to Part 3d), carcinomatous meningitis, cerebral edema, and/or progressive growth or pulmonary lymphangitic metastases.
- Current abnormal vaginal bleeding or symptomatic endometrial disorders.
- For Part 2: Use of other ET that block the estrogen receptor: atleast 8 weeks before enrollment (28 weeks for fulvestrant) For Part 2: Liver-only metastases (are not evaluable by FES-PET/CT imaging)
- For Part 3: Any brain lesion requiring immediate local therapy (which includes but is not limited to WBRT, SRS, or surgical resection, for treatment of brain metastases) Requires increase in the dose of corticosteroids for control of CNS symptoms due to brain metastases Poorly controlled (> 2 per month ) generalized or complex partial seizures Who are taking concurrent enzyme-inducing antiepileptic drugs (EIAED) Who has evidence of significant (ie, symptomatic) intracranial haemorrhage Contra indications for repeated MRI assessments
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SCO-120
|
Dose escalation cohort
Pharmacodyanamic (PD) dose exploration cohorts
Dose expansion at dose(s) ≤ maximum tolerated dose (MTD) cohort
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of dose limiting toxicities at each dose levels (Part 1 only)
Time Frame: 28 Days/End of Cycle 1
|
28 Days/End of Cycle 1
|
|
|
Incidence and severity of adverse events with each dose level
Time Frame: upto 30 days of last dose
|
The intensity of adverse events will be graded as per CTCAE, Version 5.0 and categorized as serious adverse events or non-serious adverse events.
|
upto 30 days of last dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
evaluation of Cmax (Part 1 and Part 2)
Time Frame: Through Cycle 1 and Cycle 2 (Each cycle of 28 Days)
|
Pharmacokinetic analysis will be performed using non-compartmental analysis.
The actual elapsed time from dose will be used in the final pharmacokinetic parameter calculations
|
Through Cycle 1 and Cycle 2 (Each cycle of 28 Days)
|
|
evaluation of tmax (Part 1 and Part 2)
Time Frame: Through Cycle 1 and Cycle 2 (Each cycle of 28 Days)
|
Pharmacokinetic analysis will be performed using non-compartmental analysis.
The actual elapsed time from dose will be used in the final pharmacokinetic parameter calculations
|
Through Cycle 1 and Cycle 2 (Each cycle of 28 Days)
|
|
evaluation of AUC (Part 1 and Part 2)
Time Frame: Through Cycle 1 and Cycle 2 (Each cycle of 28 Days)
|
Pharmacokinetic analysis will be performed using non-compartmental analysis.
The actual elapsed time from dose will be used in the final pharmacokinetic parameter calculations
|
Through Cycle 1 and Cycle 2 (Each cycle of 28 Days)
|
|
tumour response
Time Frame: Every 8 weeks, for 'Time point Response (Partial Response[PR], Stable Disease[SD], Disease progression [DP] or Complete Response [CR]), Through study completion, an average of 1 year.
|
Every 8 weeks, for 'Time point Response (Partial Response[PR], Stable Disease[SD], Disease progression [DP] or Complete Response [CR]), Through study completion, an average of 1 year.
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
pharmacodynamic biomarker
Time Frame: At Screening and End of Cycle 1' (Each Cycle of 28 days)
|
Pharmacodynamic Biomarkers [Estrogen receptor (ER) expression, Ki67 down regulation from Tissue Biopsy, and Estrogen receptor occupancy with [(18)F] Fluoroestradiol Positron Emission Tomography (18F-FES PET) scan]
|
At Screening and End of Cycle 1' (Each Cycle of 28 days)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SCO-120-19-22
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.